Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding | Zendy

Tripti Singh | Zendy; Thin Thin Maw | Zendy; Brian L. Henry | Zendy; Núria M. PastorSoler | Zendy; Mark L. Unruh | Zendy; Kenneth R. Hallows | Zendy; Thomas D. Nolin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding

Author(s) -

Tripti Singh,

Thin Thin Maw,

Brian L. Henry,

Núria M. PastorSoler,

Mark L. Unruh,

Kenneth R. Hallows,

Thomas D. Nolin

Publication year - 2013

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01570213

Subject(s) - medicine , dabigatran , extracorporeal membrane oxygenation , intensive care medicine , extracorporeal , anesthesia , atrial fibrillation , warfarin

Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation. No antidote is available for reversal of dabigatran's anticoagulant effect. Despite limited clinical data, hemodialysis has been suggested as a strategy to remove dabigatran during acute bleeding. This work presents five cases, in which extracorporeal therapy was performed for dabigatran removal in acutely bleeding patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research